Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
IPO Year:
Exchange: NASDAQ
Website: iovance.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $17.00 | Buy | UBS |
| 7/29/2024 | $19.00 → $10.00 | Overweight → Neutral | Piper Sandler |
| 11/20/2023 | $12.00 | Buy | Goldman |
| 9/18/2023 | $40.00 → $18.00 | Overweight | Barclays |
| 5/30/2023 | $11.00 → $17.00 | Equal Weight → Overweight | Wells Fargo |
| 3/27/2023 | $11.00 | Equal Weight | Wells Fargo |
| 1/27/2023 | $11.00 → $14.00 | Neutral → Overweight | Piper Sandler |
| 12/9/2022 | $20.00 → $6.00 | Buy → Neutral | Goldman |
| 10/31/2022 | Neutral | Guggenheim | |
| 8/18/2022 | $14.00 | Equal Weight | Wells Fargo |
SAN CARLOS, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on January 16, 2025 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 224,550 shares of Iovance's common stock to forty-one new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, Mar
SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on December 19, 2024 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 203,980 shares of Iovance's common stock to forty-eight new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022,
SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Raj Puri, M.D., Ph.D. has been promoted to the newly created role of Chief Regulatory Officer. Dr. Puri joined Iovance in March 2022 as Executive Vice President, Regulatory Strategy and Translational Medicine. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "Raj was instrumental in our successfully obtaining regulatory approval of Amtagvi™ in the United
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Nov. 14, 2024 /PRNewswire/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the American Medical Association is pointing out the alarming trend of rising cancer rates, especially with younger people. According to data released from the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH), a map shared by Newsweek showed that the prevalence of cancer varies significantly from state to state. Thankfully, there are plenty of new breakthroughs in the fight against cancer that the World Eco
Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue Marketing Authorization Applications Validated and Accepted for Review by European Regulatory Authorities for Potential Approval Starting with the UK in 1H2025 and EU and Canada in 2H2025 Enrollment Accelerating in IOV-LUN-202 Registrational Phase 2 Trial in Post-anti-PD-1 NSCLC SAN CARLOS, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lym
SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter and year to date 2024 financial results on Thursday, November 7, 2024. Q3 2024 Financial Results Conference CallManagement will host a conference call and live audio webcast to discuss these results and provide a corporate update on November 7, 2024 at 4:30 p.m. EST. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/vxykqwaf. The live and arch
SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences: Wells Fargo Healthcare ConferenceFireside Chat: September 4, 2024 at 3:45 p.m. ETBoston, MABaird Global Healthcare ConferenceFireside Chat: September 10, 2024 at 2:35 p.m. ETNew York, NYH.C. Wainwright Global Investment ConferencePresentation: September 11, 2024 at 11:00 a.m. ETNew York, NY The live and archived we
SAN CARLOS, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on August 15, 2024 (the "Date of Grant"), the Company approved the grant of inducement stock options and restricted stock units covering an aggregate of 289,710 shares of Iovance's common stock to twenty-four new, non-executive employees. The awards were granted under Iovance's 2021 Inducement Plan, which was adopted on September 22, 2021 and amended on January 12, 2022, March 13,
Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $450-$475 Million for FY25 SAN CARLOS, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter and first half 2024 financial results and corporate updates. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "The first
SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/uhudv42k/. The live and archived webcast can be accessed in the Investors section of the Company's
For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B
S-8 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
144 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
10-Q - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
S-8 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
S-8 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
10-Q - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
3 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position
SAN CARLOS, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the appointment of Wendy L. Dixon, Ph.D., to the company's Board of Directors, effective June 10, 2022. Dr. Dixon has more than 40 years of experience in the biopharmaceutical industry, building and leading organizations and launching and growing more than 20 major global pharmaceutical products, including many highly successful multibillion dollar global brands. Iain Dukes, D. Phil., Chairman of the Board of Direc
REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, announced the appointment of Franco Valle as Chief Financial Officer. Mr. Valle is an accomplished financial expert who brings extensive experiences to Biomea, in particular with building the necessary infrastructure to support clinical and operational growth within biotech companies. Mr. Valle will also assume the role of Principal Financial Officer and Principal Accounting Officer upon joining. Recently, Mr. Valle se
SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appointment of Igor Bilinsky, Ph.D., as Chief Operating Officer, effective today. Dr. Bilinsky brings more than 20 years of biotechnology industry experience as a senior executive and consultant, including public companies. “I am pleased to welcome Igor to Iovance and look forward to his contributions while we advance our TIL cell therapy pipeline,” stated Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics. “Through his experience in several senior
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13D/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
UBS initiated coverage of Iovance Biotherapeutics with a rating of Buy and set a new price target of $17.00
Piper Sandler downgraded Iovance Biotherapeutics from Overweight to Neutral and set a new price target of $10.00 from $19.00 previously
Goldman initiated coverage of Iovance Biotherapeutics with a rating of Buy and set a new price target of $12.00
Barclays reiterated coverage of Iovance Biotherapeutics with a rating of Overweight and set a new price target of $18.00 from $40.00 previously
Wells Fargo upgraded Iovance Biotherapeutics from Equal Weight to Overweight and set a new price target of $17.00 from $11.00 previously
Wells Fargo resumed coverage of Iovance Biotherapeutics with a rating of Equal Weight and set a new price target of $11.00
Piper Sandler upgraded Iovance Biotherapeutics from Neutral to Overweight and set a new price target of $14.00 from $11.00 previously
Goldman downgraded Iovance Biotherapeutics from Buy to Neutral and set a new price target of $6.00 from $20.00 previously
Guggenheim initiated coverage of Iovance Biotherapeutics with a rating of Neutral
Wells Fargo resumed coverage of Iovance Biotherapeutics with a rating of Equal Weight and set a new price target of $14.00
Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue Marketing Authorization Applications Validated and Accepted for Review by European Regulatory Authorities for Potential Approval Starting with the UK in 1H2025 and EU and Canada in 2H2025 Enrollment Accelerating in IOV-LUN-202 Registrational Phase 2 Trial in Post-anti-PD-1 NSCLC SAN CARLOS, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lym
SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter and year to date 2024 financial results on Thursday, November 7, 2024. Q3 2024 Financial Results Conference CallManagement will host a conference call and live audio webcast to discuss these results and provide a corporate update on November 7, 2024 at 4:30 p.m. EST. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/vxykqwaf. The live and arch
Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $450-$475 Million for FY25 SAN CARLOS, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter and first half 2024 financial results and corporate updates. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "The first
SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/uhudv42k/. The live and archived webcast can be accessed in the Investors section of the Company's
Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment Centers (ATCs), with ~50 Total ATCs On Track by End of May and 70+ Total ATCs by Year-End 2024 Amtagvi Regulatory Submissions on Track in the European Union (EU), United Kingdom (UK), and Canada in 2024 SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarte
SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/m4tigan7. The live and archived webcast can be accessed in the Investors section of the Company's website, I
SAN CARLOS, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full-year 2023 financial results on Wednesday, February 28, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To participate in the live conference call Q&A, please register at https://register.vevent.com/register/BI289df7d30f474a72a72e1c4f7a754c92. To listen to the live or archived audio webcast, please r
SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast to discuss the FDA approval announced earlier today at 4:15 p.m. ET, February 16, 2024. To participate in the conference call Q&A and live audio webcast, please register at https://register.vevent.com/register/BI0633b8a73e8b4c578bfed2a8ef37003e. To listen to the live or archived webcast, please register at https://edge.media-server.com/mmc/p/uqbbcfz4/. The live and archived webcast
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter and year-to-date 2023 financial results on Tuesday, November 7, 2023. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To participate in the conference call Q&A and live audio webcast, please register at https://register.vevent.com/register/BIfd1787749ef747f19a491cb371d60fab. To listen to the live or archived webcast,
SAN CARLOS, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter 2023 financial results on Tuesday, August 8, 2023. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To participate in the conference call and live audio webcast, please register at https://register.vevent.com/register/BI83559f749d674b71bae2cbaeb65d484b. To listen to the live webcast, please register at https://edge.m